Immune cell clues in breast cancer tumors may predict Long-Term survival

NCT ID NCT07545434

Completed Knowledge-focused Sponsor: Hellenic Cooperative Oncology Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined tumor samples from 3,646 women with early-stage breast cancer who had already received chemotherapy after surgery. Researchers measured specific immune cells (tumor-infiltrating lymphocytes and CD8+ T cells) to see if their presence was linked to how long patients lived without their cancer returning. The goal was to better understand the role of the immune system in fighting breast cancer and potentially improve risk prediction.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this analysis could help doctors better predict which early breast cancer patients are at higher risk of recurrence, guiding more personalized treatment decisions.
What could go wrong: This is an observational analysis of existing data, not a test of a new treatment. The findings may not change current practice without further validation in prospective studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EARLY BREAST CANCER

Contacts and locations

Locations

Hellenic Cooperative Oncology Group

Athens, 11526, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.